Abstract 46P
Background
The mechanism of PD-1 inhibitors-induced myocarditis in individuals with tumor is still unclear. Regulatory T cells (Treg) can directly inhibit T cell proliferation and activation, and also produce inhibitory cytokines with potent immunosuppressive properties. Deletion or aberrant function of Treg usually leads to autoimmune diseases. But reports on the role of Treg in PD-1 inhibitor-associated myocarditis are still very limited, and its role in the pathogenesis of myocarditis needs to be further explored. In addition, alterations in the composition of the gut microbiota and its metabolites have been shown to be involved in the development of several cardiovascular and autoimmune diseases.
Methods
We first established a melanoma model in mice, which were subsequently divided into three groups: control group, Anti-PD1 group and fecal microbiota removal (FMR) group. The control group and Anti-PD1 group were subcutaneously injected with mouse IgG and PD-1 inhibitors respectively, and FMR group were injected with PD-1 inhibitors subcutaneously along with oral antibiotic antimicrobials to clear the intestinal microbiota. Afterwards, we assessed the severity of myocarditis in mice, performed flow cytometry analysis of immune cells in the heart, determined transcript levels of Treg-related cytokines in the heart, and performed 16S rRNA gene sequence analysis of gut microbiota and correlation analysis of enriched gut microbiota with myocarditis factors.
Results
PD-1 inhibitors induced myocarditis in melanoma mice, leading to a reduction in intracardiac Tregs and downregulation of inflammatory suppressor transcript levels, as well as altering the gut microbial composition of the mice. However, in the presence of gut microbial removal, myocarditis manifestations in the mice described above were attenuated. In addition, microbes enriched in the gut of mice after treatment with PD-1 inhibitors showed a strong correlation with factors associated with the development of myocarditis.
Conclusions
PD-1 inhibitors induced myocarditis and significant reduction of intracardiac Treg in melanoma mice. It is highly likely that alterations in the composition of the gut microbiota due to PD-1 inhibitors played a key role in this process.
Legal entity responsible for the study
The authors.
Funding
Shanxi Provincial Health Commission.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
156P - Liver Metastases Correlate with Shortened Survival and Increased Dissociate Response in Patients Treated with T-Cell Engagers.
Presenter: Noé Herbel
Session: Poster Display session
Resources:
Abstract
157P - Preliminary results of a multicentric randomized phase I/IIa trial of an immunotherapy targeting dendritic cells (DC), CD40HVac, in patients with HPV16-positive oropharyngeal carcinoma (OPC)
Presenter: Caroline Even
Session: Poster Display session
Resources:
Abstract
158P - XCR1+ dendritic cell (DC) role in antitumoral response to anti PD-L1 antibody: Data from the phase Ib/II trial of DC vaccination in small cell lung cancer patients
Presenter: Maria Gonzalez Cao
Session: Poster Display session
Resources:
Abstract
159P - Unveiling the impact of DC vaccination on systemic immunity in advanced malignant melanoma: Preliminary results from the ABSIDE study
Presenter: Giada Sabatino
Session: Poster Display session
Resources:
Abstract
160P - Oral DNA vaccination targeting personalised neoantigens in immune checkpoint-inhibitor treated solid tumor patients: Interim results
Presenter: Domas Vaitiekus
Session: Poster Display session
Resources:
Abstract
161P - Safety of TrimelVax vaccine for patients with advanced melanoma: Clinical results
Presenter: ROBERTO ESTAY
Session: Poster Display session
Resources:
Abstract
162P - EO4010 (EO) + nivolumab (N) ± bevacizumab (B) in patients (pts) with microsatellite stable (MSS) metastatic colorectal carcinoma (mCRC)
Presenter: Romain Cohen
Session: Poster Display session
Resources:
Abstract
163P - Effect of split intravenous dosing of oncolytic adenovirus TILT-123 on normal tissue versus tumor macrophages and virus bioavailability in patients with advanced solid tumors
Presenter: Elise Jirovec
Session: Poster Display session
Resources:
Abstract
164P - Roginolisib (IOA-244), the first highly selective oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_), has immuno-modulatory effects associated with clinical benefits in patients with metastatic uveal melanoma
Presenter: Anna Di Giacomo
Session: Poster Display session
Resources:
Abstract
165P - TIGIT inhibition in non-small cell lung cancer: Meta-analysis of clinical efficacy and biomarker correlation
Presenter: Hashim Talib Hashim
Session: Poster Display session
Resources:
Abstract